AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29530884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study 30265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layered plasty using lightweight partially absorbable net (LPAN) Ultrapro (group II)
Number of subjects: 0
Study 30265463 — intervention group
Group type: COMPARATOR
Intervention: Cruroraphy (group I)
Number of subjects: 0
Study 30265463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 24888295 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC eating in post‐pubertal youth
Number of subjects: 468
Study 24888295 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC eating in late‐puberty youth
Number of subjects: 468
Study 24888295 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC eating in pre‐pubertal youth
Number of subjects: 468
Study 24888295 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered eating attitudes and palatable food consumption
Number of subjects: 468
Study 22337760 — intervention group
Group type: EXPERIMENTAL
Intervention: MABP maintained between 60‐70 mmHg (MP group, n=50)
Number of subjects: 122
Study 22337760 — intervention group
Group type: EXPERIMENTAL
Intervention: MABP <60 mmHg (LP group, n=36)
Number of subjects: 122
Study 22337760 — intervention group
Group type: EXPERIMENTAL
Intervention: MABP >70 mmHg (HP group, n=36)
Number of subjects: 122
Study 22337760 — intervention group
Group type: COMPARATOR
Intervention: All groups (MP, LP, HP)
Number of subjects: 122
Study 20579167 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of stimuli (music, social stimuli, simulated social stimuli, individualized stimuli based on self-identity)
Number of subjects: 111
Study 20579167 — intervention group
Group type: EXPERIMENTAL
Intervention: Live social stimuli
Number of subjects: 111
Study 20579167 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and reading stimuli
Number of subjects: 111
Study 20579167 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and self-identity stimuli
Number of subjects: 111
Study 20579167 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative stimuli
Number of subjects: 111
Study 17593865 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (200 microg once daily)
Number of subjects: 40
Study 17593865 — intervention group
Group type: COMPARATOR
Intervention: BUD-TH (400 microg twice daily)
Number of subjects: 40
Study 17593865 — intervention group
Group type: COMPARATOR
Intervention: FP-IH (250 microg twice daily)
Number of subjects: 40
Study 15677301 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored nutrition intervention
Number of subjects: 782
Study 15677301 — intervention group
Group type: COMPARATOR
Intervention: Generic nutrition information control group
Number of subjects: 782
Study 15677301 — intervention group
Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 782
Study 12374629 — intervention group
Group type: EXPERIMENTAL
Intervention: clomipramine+lithium (C+L)
Number of subjects: 10
Study 12374629 — intervention group
Group type: COMPARATOR
Intervention: clomipramine+placebo (C+P)
Number of subjects: 10
Study 10357419 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CRT with a minimum tumor dose of 64.8 Gy to 81.0 Gy
Number of subjects: 743
Study 8596484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic-phase insulin response (CPIR) before weight reduction
Number of subjects: 20
Study 8596484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic-phase insulin response (CPIR) after weight reduction
Number of subjects: 20
Study 8596484 — intervention group
Group type: EXPERIMENTAL
Intervention: First-phase insulin secretion during intravenous glucose tolerance test (IVGTT)
Number of subjects: 20
Study 8596484 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CPIR measurements before and after weight reduction
Number of subjects: 20
Study 1763606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 35
Study 1763606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 35
Study 1763606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 35
Study 1763606 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol
Number of subjects: 35
Study 1763606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6121965 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa treatment during pregnancy
Number of subjects: 195
Study 6121965 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 195
Study 6121965 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa treatment
Number of subjects: 195
Study 30346340 — intervention group
Group type: EXPERIMENTAL
Intervention: Impression Cytology using EYEPRIM device with topical anesthesia
Number of subjects: 46
Study 30346340 — intervention group
Group type: EXPERIMENTAL
Intervention: Impression Cytology using EYEPRIM device without topical anesthesia
Number of subjects: 46
Study 30346340 — intervention group
Group type: EXPERIMENTAL
Intervention: Droplet digital PCR
Number of subjects: 46
Study 30261237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 1448
Study 30261237 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 1448
Study 30261237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance with successful procedures
Number of subjects: 1448
Study 30261237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance with failed procedures
Number of subjects: 1448
Study 26933886 — intervention group
Group type: EXPERIMENTAL
Intervention: AndoSan™ (n = 24)
Number of subjects: 50
Study 26933886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 50
Study 24945194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg once daily for 3 months)
Number of subjects: 39
Study 24945194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching oral placebo for 3 months)
Number of subjects: 39
Study 24945194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg to 200 mg daily for 3 months, open-label follow-up)
Number of subjects: 39
Study 24945194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during open-label follow-up)
Number of subjects: 39
Study 24945194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 39
Study 24945194 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (open-label follow-up)
Number of subjects: 39
Study 22677489 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary understanding of MFH for management decisions
Number of subjects: 0
Study 22677489 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature review on MFH and undifferentiated pleomorphic sarcoma
Number of subjects: 0
Study 22677489 — intervention group
Group type: EXPERIMENTAL
Intervention: Advances in the conception of MFH
Number of subjects: 0
Study 21052881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg before surgery and 150 mg every 8 hours
Number of subjects: 100
Study 21052881 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg before surgery and 550 mg every 12 hours
Number of subjects: 100
Study 21052881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17107734 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (IFN-alpha)
Number of subjects: 233
Study 17107734 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 233
Study 16274344 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 sessions of comprehensive exercise-based outpatient cardiac rehabilitation
Number of subjects: 113
Study 16274344 — intervention group
Group type: COMPARATOR
Intervention: Conventional care as provided by the treating doctor
Number of subjects: 113
Study 12894011 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupét partial fundoplication
Number of subjects: 95
Study 12894011 — intervention group
Group type: COMPARATOR
Intervention: Watson partial fundoplication
Number of subjects: 95
Study 10051804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 530
Study 10051804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 7864427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 MAC desflurane
Number of subjects: 0
Study 7864427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 MAC isoflurane
Number of subjects: 0
Study 7864427 — intervention group
Group type: COMPARATOR
Intervention: Control (no information supplied)
Number of subjects: 0
Study 2288141 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid 500 mg once a day
Number of subjects: 46
Study 2288141 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 2288141 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 46
Study 6780210 — intervention group
Group type: EXPERIMENTAL
Intervention: spectinomycin
Number of subjects: 420
Study 6780210 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin-probenocid
Number of subjects: 420
Study 6780210 — intervention group
Group type: EXPERIMENTAL
Intervention: thiamphenicol
Number of subjects: 420
Study 6780210 — intervention group
Group type: EXPERIMENTAL
Intervention: minocyclin
Number of subjects: 420
Study 31529104 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy
Number of subjects: 240
Study 31529104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonopioid medication therapy
Number of subjects: 240
Study 28893144 — intervention group
Group type: EXPERIMENTAL
Intervention: TCL reconstruction group (n=59)
Number of subjects: 117
Study 28893144 — intervention group
Group type: COMPARATOR
Intervention: TCL release group (n=58)
Number of subjects: 117
Study 26685082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-nurse communication topics (family questions, family dynamics, spiritual/religious issues, cultural issues)
Number of subjects: 1173
Study 26685082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-family communication ratings (answering family's questions, listening to family, asking about treatments patient would want, helping family decide patient's treatment wishes, overall communication)
Number of subjects: 1173
Study 26685082 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physician-family communication and helping family incorporate patient's wishes
Number of subjects: 1173
Study 26685082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' concerns for patient or family
Number of subjects: 1173
Study 23848231 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus black seed and garlic
Number of subjects: 300
Study 23848231 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin plus placebo
Number of subjects: 300
Study 21828231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg
Number of subjects: 627
Study 21828231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 400 μg
Number of subjects: 627
Study 21828231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 600 μg
Number of subjects: 627
Study 21828231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 800 μg
Number of subjects: 627
Study 21828231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg
Number of subjects: 627
Study 21828231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 20386129 — intervention group
Group type: EXPERIMENTAL
Intervention: Precompetition massage
Number of subjects: 20
Study 20386129 — intervention group
Group type: COMPARATOR
Intervention: Traditional warm-up
Number of subjects: 20
Study 20386129 — intervention group
Group type: EXPERIMENTAL
Intervention: Precompetition massage combined with traditional warm-up
Number of subjects: 20
Study 20386129 — intervention group
Group type: COMPARATOR
Intervention: Massage alone
Number of subjects: 20
Study 18278078 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income tertiles) in Australia
Number of subjects: 8733
Study 18278078 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status (income tertiles) in New Zealand
Number of subjects: 8733
Study 18278078 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status (income tertiles) in New Zealand vs Australia
Number of subjects: 8733
Study 18278078 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity, smoking, and high white blood cell count at baseline
Number of subjects: 8733
Study 18278078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication, percutaneous coronary intervention, and coronary artery bypass surgery
Number of subjects: 8733
Study 15776502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (test)
Number of subjects: 26
Study 15776502 — intervention group
Group type: COMPARATOR
Intervention: Diflucan (reference)
Number of subjects: 26
Study 11828038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaja yoga intervention (2 hour session once a week for 4 months)
Number of subjects: 59
Study 11828038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaja yoga intervention
Number of subjects: 59
Study 11828038 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (2 hour session once a week for 4 months)
Number of subjects: 59
Study 11828038 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 59
Study 9933795 — intervention group
Group type: EXPERIMENTAL
Intervention: BTA stat test
Number of subjects: 240
Study 9933795 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 240
Study 7500601 — intervention group
Group type: EXPERIMENTAL
Intervention: VII/(81) scheme
Number of subjects: 74
Study 7500601 — intervention group
Group type: COMPARATOR
Intervention: LSA2L2 scheme
Number of subjects: 74
Study 2258635 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha‐2b (rIFN alpha 2b) therapy for a total period of 20 months
Number of subjects: 68
Study 2258635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 68
Study 6778264 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-precipitated grass extract
Number of subjects: 0
Study 6778264 — intervention group
Group type: COMPARATOR
Intervention: Glycerosaline grass extract
Number of subjects: 0
Study 31656057 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST intervention (2 days of off-site training of influential students to encourage peers not to smoke during a 10-week period)
Number of subjects: 10730
Study 31656057 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST intervention
Number of subjects: 10730
Study 31656057 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual education)
Number of subjects: 10730
Study 30955444 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring earlier in the OSCE
Number of subjects: 228
Study 30955444 — intervention group
Group type: COMPARATOR
Intervention: Scoring later in the OSCE
Number of subjects: 228
Study 30955444 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of DRIFT (specifically primacy)
Number of subjects: 228
Study 30955444 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall influence of DRIFT on test outcomes
Number of subjects: 228
Study 28408798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SKA cytokines (IL-4, IL-10, anti-IL-1 antibodies at 10 fg/mL, orally administered at a dose of 20 drops/d for 12 months)
Number of subjects: 39
Study 28408798 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying antirheumatic drugs (DMARDs) therapy
Number of subjects: 39
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^4 spores/d for 7 days)
Number of subjects: 173
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^7 spores/d for 7 days)
Number of subjects: 173
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (10^7 spores/d for 14 days)
Number of subjects: 173
Study 25942722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 173
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (all doses combined)
Number of subjects: 173
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (colonized patients)
Number of subjects: 173
Study 25942722 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCD-M3 (not colonized patients)
Number of subjects: 173
Study 23645372 — intervention group
Group type: EXPERIMENTAL
Intervention: PR ortho-k
Number of subjects: 52
Study 23645372 — intervention group
Group type: COMPARATOR
Intervention: Control (single-vision spectacles)
Number of subjects: 52
Study 21748912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10
Study 21748912 — intervention group
Group type: COMPARATOR
Intervention: Control, low-fat meal
Number of subjects: 10
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (fluoxetine + cognitive-behavioral therapy)
Number of subjects: 439
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 439
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all active treatments)
Number of subjects: 439
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase remitters
Number of subjects: 439
Study 19127172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase remitters
Number of subjects: 439
Study 17101261 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg)
Number of subjects: 14
Study 17101261 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 14
Study 15318251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (4 ml/kg, 1.8 meq/kg)
Number of subjects: 55
Study 15318251 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (Control)
Number of subjects: 55
Study 11289198 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy for early syphilis
Number of subjects: 526
Study 11289198 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for early syphilis
Number of subjects: 526
Study 11289198 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic complaints
Number of subjects: 526
Study 9260006 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal pain treatment with intrathecal morphine, incisional bupivacaine and ibuprofen+acetaminophen po until hospital discharge (Group 1)
Number of subjects: 40
Study 9260006 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with iv PCA morphine weaned to acetaminophen+codeine po (Group 2)
Number of subjects: 40
Study 9260006 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 40
Study 7974091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation (VR) assistance through intensive outreach, case management, and enhanced work incentives.
Number of subjects: 0
Study 7974091 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 2481832 — intervention group
Group type: EXPERIMENTAL
Intervention: Esberitox N
Number of subjects: 70
Study 30861167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education
Number of subjects: 111
Study 30861167 — intervention group
Group type: COMPARATOR
Intervention: Standard care advice (Control)
Number of subjects: 111
Study 26429609 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution, 10%
Number of subjects: 1655
Study 26429609 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1655
Study 23525631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative double-J stent (group 1)
Number of subjects: 68
Study 23525631 — intervention group
Group type: COMPARATOR
Intervention: Overnight-externalized ureteral catheter (group 2)
Number of subjects: 68
Study 21933100 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (OMA) added to optimized asthma therapy (OAT) for 32 weeks
Number of subjects: 82
Study 21933100 — intervention group
Group type: COMPARATOR
Intervention: Optimized asthma therapy (OAT) alone for 32 weeks
Number of subjects: 82
Study 18199474 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cotinine concentration
Number of subjects: 66
Study 18199474 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 66
Study 18199474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 66
Study 16600583 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg niacin orally
Number of subjects: 47
Study 14709924 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10766183 — intervention group
Group type: COMPARATOR
Intervention: GM‐CSF alone (2.5 microg/kg/day)
Number of subjects: 1
Study 10766183 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF in combination with IL‐4 (0.5‐6.0 microg/kg/day)
Number of subjects: 1
Study 10766183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (GM‐CSF and IL‐4)
Number of subjects: 1
Study 8777364 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES) 200/0.62
Number of subjects: 12
Study 8777364 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 200/0.62
Number of subjects: 12
Study 1864787 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 6
Study 1864787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose, 5 mg/kg)
Number of subjects: 6
Study 1864787 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 W)
Number of subjects: 6
Study 1864787 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 6
Study 6195021 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% dextran 70
Number of subjects: 102
Study 6195021 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 102
Study 31854365 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival control (Supra)
Number of subjects: 25